| Trial ID: | L2126 |
| Source ID: | NCT00845182
|
| Associated Drug: |
Pioglitazone
|
| Title: |
Effect of Pioglitazone and Exenatide on Body Weight and Beta Cell Function
|
| Acronym: |
PIO-EX
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT00845182/results
|
| Conditions: |
Type 2 Diabetes|Healthy|Impaired Glucose Tolerance
|
| Interventions: |
DRUG: Pioglitazone|DRUG: Exenatide|DRUG: Pioglitazone and Exenatide
|
| Outcome Measures: |
Primary: Effect of Pioglitazone, Exenatide and Combined Pioglitazone and Exenatide on Body Weight, Effect of Pioglitazone, Exenatide and combined Pioglitazone and Exenatide on body weight and beta cell function, baseline and 6 months|HbA1c, change in HbA1c was measured before and after treatment in three groups, baseline and 6 months | Secondary: Effect Pioglitazone, Exenatide, and Pioglitazone Plus Exenatide • Insulin Sensitivity • Inflammatory Cytokines • Glucagon and Free Fatty Acids • Plasma Lipids, Effect pioglitazone, exenatide, and pioglitazone plus exenatide on * Insulin sensitivity * Inflammatory cytokines * glucagon and free fatty acids * plasma lipids measured over a 6 month period, 6 months
|
| Sponsor/Collaborators: |
Sponsor: The University of Texas Health Science Center at San Antonio
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
43
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT
|
| Start Date: |
2007-06
|
| Completion Date: |
2010-07
|
| Results First Posted: |
2015-03-17
|
| Last Update Posted: |
2018-01-18
|
| Locations: |
Barter Research Center, ALM VA Hospital, San Antonio, Texas, 78229, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00845182
|
